Artesunate intravenous - US Army Medical Material Development Activity/Walter Reed Army Institute of Research
Alternative Names: Artesunate intravenous project - MMV00/1013; Artesunate IV; Artesunate IV project - MMV00/1013; Intravenous artesunate; IV artesunate; NuartezLatest Information Update: 23 Jun 2022
At a glance
- Originator U.S. Army Medical Materiel Development Activity; Walter Reed Army Institute of Research
- Developer Amivas; U.S. Army Medical Material Development Activity; Walter Reed Army Institute of Research
- Class 3-ring heterocyclic compounds; Antimalarials; Artemisinins; Small molecules; Succinates
- Mechanism of Action Reactive oxygen species stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Malaria
Most Recent Events
- 13 Jun 2022 Preregistration for Malaria (In adults, In children) in United Kingdom (IV) on or before June 2022
- 13 Jun 2022 Registered for Malaria (In children, In adults) in United Kingdom (IV)
- 13 Jun 2022 Amivas plans to launch Artesunate for the treatment of Malaria (In adults, In children) in United Kindom (IV, injection) on or before Q1 2023